医学物理学
医学
监管机构
临床试验
风险分析(工程)
病理
政治学
公共行政
作者
Aruna Korde,Renata Mikołajczak,Petra Kolenc Peitl,Penelope Bouziotis,Hadis Westin,M. Lauritzen,Michel Koole,Matthias M. Herth,Manuel Bardiès,André F. T. Martins,António Paulo,Serge K. Lyashchenko,Sergio Todde,Sangram Nag,Efthymios Lamprou,Antero Abrunhosa,Francesco Giammarile,Clemens Decristoforo
标识
DOI:10.1186/s41181-022-00168-x
摘要
The development of radiopharmaceuticals requires extensive evaluation before they can be applied in a diagnostic or therapeutic setting in Nuclear Medicine. Chemical, radiochemical, and pharmaceutical parameters must be established and verified to ensure the quality of these novel products.To provide supportive evidence for the expected human in vivo behaviour, particularly related to safety and efficacy, additional tests, often referred to as "non-clinical" or "preclinical" are mandatory. This document is an outcome of a Technical Meeting of the International Atomic Energy Agency. It summarises the considerations necessary for non-clinical studies to accommodate the regulatory requirements for clinical translation of radiopharmaceuticals. These considerations include non-clinical pharmacology, radiation exposure and effects, toxicological studies, pharmacokinetic modelling, and imaging studies. Additionally, standardisation of different specific clinical applications is discussed.This document is intended as a guide for radiopharmaceutical scientists, Nuclear Medicine specialists, and regulatory professionals to bring innovative diagnostic and therapeutic radiopharmaceuticals into the clinical evaluation process in a safe and effective way.
科研通智能强力驱动
Strongly Powered by AbleSci AI